5-[4-(三氟甲氧基)苯基]呋喃-2-甲酸 | 638160-01-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 中文名称: 5-[4-(三氟甲氧基)苯基]呋喃-2-甲酸
• 英文名称: 5-((4-trifluoromethoxy)phenyl)furan-2-carboxylic acid
• 英文别名: 5-[4-(Trifluoromethoxy)phenyl]furan-2-carboxylic acid
• CAS: 638160-01-7
• 化学式: C₁₂H₇F₃O₄
• mdl: MFCD02215949
• 分子量: 272.18
• InChiKey: KHCLEQZLFHIDBP-UHFFFAOYSA-N

物化性质

• 沸点：
  355.9±42.0 °C(Predicted)
• 密度：
  1.429±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.083
• 拓扑面积：
  59.7
• 氢给体数：
  1
• 氢受体数：
  7

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-[4-(三氟甲氧基)苯基]呋喃-2-甲酸 、 1-氨基-3,5-二甲苯 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-(3,5-dimethylphenyl)-5-(4-(trifluoromethoxy)phenyl)furan-2-carboxamide
  参考文献：
  名称：

  Subtype-selective Nav1.8 sodium channel blockers: Identification of potent, orally active nicotinamide derivatives

  摘要：

  A series of aryl-substituted nicotinamide derivatives with selective inhibitory activity against the Na(v)1.8 sodium channel is reported. Replacement of the furan nucleus and homologation of the anilide linker in subtype-selective blocker A-803467 (1) provided potent, selective derivatives with improved aqueous solubility and oral bioavailability. Representative compounds from this series displayed efficacy in rat models of inflammatory and neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.121
• 作为产物：
  描述：

  5-溴-2-糠酸甲酯 在 甲醇 、 四(三苯基膦)钯 、 sodium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 19.0h， 生成 5-[4-(三氟甲氧基)苯基]呋喃-2-甲酸
  参考文献：
  名称：

  Hedgehog信号通路抑制剂

  摘要：

  本发明提供的Hedgehog信号通路抑制剂及其立体异构体、互变异构体、水合物、溶剂化物或医药上可接受的盐，其结构式如式(I)所示。本发明还提供了上述化合物的制备方法与用途。本发明提供的化合物结构新颖，由Hedgehog蛋白、Ptch、Gli和/或Smo调节的信号传导通路均可以通过式I化合物予以调节。

  公开号：

  CN103992311B

文献信息

• Inhibitors of cathepsin S
  申请人：IRM LLC

  公开号：US20040198780A1

  公开（公告）日：2004-10-07

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了用于选择性抑制蛋白酶S的化合物、组合物和方法。在一个优选方面，当至少存在另一种蛋白酶同工酶（例如，蛋白酶K）时，选择性地抑制蛋白酶S。本发明还提供了通过选择性抑制蛋白酶S来治疗受试者疾病状态的方法。
• Discovery and Biological Evaluation of 5-Aryl-2-furfuramides, Potent and Selective Blockers of the Na_v1.8 Sodium Channel with Efficacy in Models of Neuropathic and Inflammatory Pain
  作者：Michael E. Kort、Irene Drizin、Robert J. Gregg、Marc J. C. Scanio、Lei Shi、Michael F. Gross、Robert N. Atkinson、Matthew S. Johnson、Gregory J. Pacofsky、James B. Thomas、William A. Carroll、Michael J. Krambis、Dong Liu、Char-Chang Shieh、XuFeng Zhang、Gricelda Hernandez、Joseph P. Mikusa、Chengmin Zhong、Shailen Joshi、Prisca Honore、Rosemarie Roeloffs、Kennan C. Marsh、Bernard P. Murray、Jinrong Liu、Stephen Werness、Connie R. Faltynek、Douglas S. Krafte、Michael F. Jarvis、Mark L. Chapman、Brian E. Marron

  DOI：10.1021/jm070637u

  日期：2008.2.1

  Na(v)1.8 (also known as PN3) is a tetrodotoxin-resistant (TTx-r) voltage-gated sodium channel (VGSC) that is highly expressed on small diameter sensory neurons and has been implicated in the pathophysiology of inflammatory and neuropathic pain. Recent studies using an Na(v)1.8 antisense oligonucleotide in an animal model of chronic pain indicated that selective blockade of Na(v)1.8 was analgesic and could provide effective analgesia with a reduction in the adverse events associated with nonselective VGSC blocking therapeutic agents. Herein, we describe the preparation and characterization of a series of 5-substituted 2-furfuramides, which are potent, voltage-dependent blockers (IC50 < 10 nM) of the human Na(v)1.8 channel. Selected derivatives, such as 7 and 27, also blocked TTx-r sodium currents in rat dorsal root ganglia (DRG) neurons with comparable potency and displayed > 100-fold selectivity versus human sodium (Na(v)1.2, Na(v)1.5, Na(v)1.7) and human ether-a-go-go (hERG) channels. Following systemic administration, compounds 7 and dose-dependently reduced neuropathic and inflammatory pain in experimental rodent models.
• US7109243B2
  申请人：——

  公开号：US7109243B2

  公开（公告）日：2006-09-19
• [EN] INHIBITORS OF CATHEPSIN S<br/>[FR] INHIBITEURS DE CATHEPSINE S
  申请人：IRM LLC

  公开号：WO2004084842A2

  公开（公告）日：2004-10-07

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
• Subtype-selective Nav1.8 sodium channel blockers: Identification of potent, orally active nicotinamide derivatives
  作者：Michael E. Kort、Robert N. Atkinson、James B. Thomas、Irene Drizin、Matthew S. Johnson、Matthew A. Secrest、Robert J. Gregg、Marc J.C. Scanio、Lei Shi、Ahmed H. Hakeem、Mark A. Matulenko、Mark L. Chapman、Michael J. Krambis、Dong Liu、Char-Chang Shieh、XuFeng Zhang、Gricelda Simler、Joseph P. Mikusa、Chengmin Zhong、Shailen Joshi、Prisca Honore、Rosemarie Roeloffs、Stephen Werness、Brett Antonio、Kennan C. Marsh、Connie R. Faltynek、Douglas S. Krafte、Michael F. Jarvis、Brian E. Marron

  DOI：10.1016/j.bmcl.2010.08.121

  日期：2010.11

  A series of aryl-substituted nicotinamide derivatives with selective inhibitory activity against the Na(v)1.8 sodium channel is reported. Replacement of the furan nucleus and homologation of the anilide linker in subtype-selective blocker A-803467 (1) provided potent, selective derivatives with improved aqueous solubility and oral bioavailability. Representative compounds from this series displayed efficacy in rat models of inflammatory and neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.